|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tomorrow 2001: Lung Cancer
Datamonitor, Jan 2002
Lung Cancer is currently served by cytotoxic agents, however, survival rates have not improved over the last decade. With a high level of unmet need, innovative products are expected to achieve high clinical uptake. In particular, AstraZeneca''s Iressa will make considerable impact in the lung cancer market in the next five years. Datamonitor''s ‘Drugs of Tomorrow 2002: Lung Cancer -Iressa Driving The Pipeline Market’ provides in-depth analysis of the key pipeline drugs for lung cancer in the seven major pharmaceutical markets including: US, Japan, UK, France, Germany, Spain, Italy. You gain access to: • Accurate and up-to-date R&D information on the focus and direction of the major players in the lung cancer market • Identification of the unmet needs in lung cancer, in drug classes and product pipelines • In-depth comparative analysis of levels of unmet need, R&D focus, drug class and pipeline products for lung cancer • Forecasts of the market potential for each individual drug profiled and predicted for launch between 2002 and 2008
Customers who bought this item also bought
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old Regimens
Treatment Algorithms 2001: Lung Cancer
Drugs of Tomorrow 2001: Cancer Overview
Drugs of Tomorrow: Cancer Overview
Innovative Agents in Lung and Colorectal Cancer - Another Step Nearer the Revolution?
Non-Small Cell Lung Cancer - Avastin to Lead the Market
Drugs of Tomorrow 2002: Colorectal Cancer
Chinese Markets for Cancer Treatment Drugs
|
|
|
|
